Doctiplus - We are allways here!
Cancer & Oncology
Weekly Report
- 132 new clinical trials registered across 10 countries.
- 18,827 trials actively recruiting patients worldwide.
- Notable trial: Screening and the Future of Enhanced MRI for Early Breast Cancer Detection (2628 patients).
- 2,381 new research papers published.
- Drug safety: Most reported effect across tracked medications (pembrolizumab, nivolumab, trastuzumab, rituximab, paclitaxel) was Off Label Use.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Cancer & Oncology. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
132 trials registered for Cancer & Oncology. Each links to its full record on ClinicalTrials.gov.
| # | Trial ↓ | Phase ↕ | Status ↕ | Enrollment ↕ | Country ↕ |
|---|---|---|---|---|---|
| 01 | Repurposing Mefloquine for Pancreatic Cancer Treatment Cancer & Oncology · University of Florida (NCT07875907) | Phase 1 | Not Yet Recruiting | 36 | N/A |
| 02 | Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC Cancer & Oncology · Telix Pharmaceuticals (Innovations) Pty Limited (NCT07870746) | Phase 2 | Not Yet Recruiting | 40 | United States |
| 03 | Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies Cancer & Oncology · Odense University Hospital (NCT07878208) | Other | Not Yet Recruiting | 50 | Denmark |
| 04 | This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to Enable More Personalized and Effective Treatments, and to Identify and Functionally Validate, at the Single-cell Level, Biomarkers That Can Predict Response to Venetoclax. Cancer & Oncology · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (NCT07874100) | Other | Recruiting | 420 | Italy |
| 05 | Screening and the Future of Enhanced MRI for Early Breast Cancer Detection Cancer & Oncology · Radboud University Medical Center (NCT07878377) | Other | Not Yet Recruiting | 2,628 | N/A |
| 06 | A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC) Cancer & Oncology · Shanghai Junshi Bioscience Co., Ltd. (NCT07876557) | Phase 2 | Not Yet Recruiting | 184 | China |
| 07 | Vascular Resection in Robotic Pancreaticoduodenectomy for Pancreatic Cancer Cancer & Oncology · Taipei Veterans General Hospital, Taiwan (NCT07871045) | Other | Completed | 239 | Taiwan |
| 08 | PMOS in OSA Pilot Study Cancer & Oncology · University of Chicago (NCT07871149) | Other | Recruiting | 10 | United States |
| 09 | Artificial Intelligence Software (Prostate Intelligence) for Detecting Clinically Significant Prostate Cancer on MRI Cancer & Oncology · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (NCT07875491) | Other | Not Yet Recruiting | 226 | Italy |
| 10 | Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Cancer & Oncology · National Cancer Center, Japan (NCT07872722) | Phase 2 | Recruiting | 29 | Japan |
| 11 | Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study Cancer & Oncology · MedPacto, Inc. (NCT07878364) | Other | Recruiting | 400 | South Korea |
| 12 | Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck Cancer & Oncology · Vanderbilt-Ingram Cancer Center (NCT07869823) | Phase 1 | Recruiting | 25 | United States |
| 13 | Home-Based Exercise and Vagus Nerve Stimulation for Chemotherapy-Induced Neuropathy Cancer & Oncology · The Hong Kong Polytechnic University (NCT07877558) | Other | Not Yet Recruiting | 60 | Hong Kong |
| 14 | Low Load Blood Flow Restriction Resistance Training in Colorectal Cancer Related Sarcopenia Cancer & Oncology · Ahmed Adel Ahmed Elsayed Ali Radwan (NCT07874035) | Other | Recruiting | 54 | Egypt |
| 15 | Feasibility Study of a Co-Designed Gamified Medical Yoga App for Home-Based Cancer Rehabilitation Cancer & Oncology · Linkoeping University (NCT07872956) | Other | Recruiting | 10 | Sweden |
| 16 | Efficacy of Complete Decongestive Therapy for Limb Lymphedema: Response Profile and Predictive Modeling Cancer & Oncology · Ryazan State Medical University (NCT07878598) | Other | Completed | 150 | Russia |
| 17 | Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study Cancer & Oncology · Hunan Province Tumor Hospital (NCT07878871) | Phase 2 | Not Yet Recruiting | 27 | China |
| 18 | Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Cancer & Oncology · Xijing Hospital (NCT07876154) | Phase 2 | Recruiting | 34 | China |
| 19 | A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer Cancer & Oncology · Hinova Pharmaceuticals Inc. (NCT07875881) | Phase 3 | Not Yet Recruiting | 1,044 | China |
| 20 | Histotripsy x Pancreatic Cancer Cancer & Oncology · The University of Hong Kong (NCT07873606) | Other | Recruiting | 20 | Hong Kong |
| 21 | Machine Learning for Transfusion Prediction in Oncologic Surgery Cancer & Oncology · Kocaeli City Hospital (NCT07875114) | Other | Active Not Recruiting | 950 | Turkey (Türkiye) |
| 22 | Magnesium Supplementation for the Prevention of Cisplatin-Induced Nephrotoxicity Cancer & Oncology · Grigore T. Popa University of Medicine and Pharmacy (NCT07874373) | Other | Completed | 43 | Romania |
| 23 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1203 in Advanced Solid Tumors. Cancer & Oncology · Shandong Boan Biotechnology Co., Ltd (NCT07876609) | Phase 1 | Recruiting | 120 | China |
| 24 | MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC Cancer & Oncology · Peking University People's Hospital (NCT07873086) | Other | Not Yet Recruiting | 50 | China |
| 25 | Protocol for Non-invasive Gynaecological Surveillance in Lynch Syndrome Cancer & Oncology · University of Edinburgh (NCT07877779) | Other | Not Yet Recruiting | 450 | United Kingdom |
| 26 | Hugo™ Robotic Assisted Surgery (RAS) System in Prostatectomy Patients Treated in an ASC Setting Cancer & Oncology · Central Ohio Urology Group (NCT07875192) | Other | Recruiting | 100 | United States |
| 27 | PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study Cancer & Oncology · M.D. Anderson Cancer Center (NCT07874828) | Phase 2 | Not Yet Recruiting | 30 | United States |
| 28 | "AFRONTA Emotional Care" Intervention for Family Caregivers of Children With Cancer. Cancer & Oncology · Universidad de Guanajuato (NCT07874958) | Other | Completed | 14 | Mexico |
| 29 | NURSE-led Geriatric Assessment in Older Colorectal Cancer Patients Cancer & Oncology · Helse Stavanger HF (NCT07872787) | Other | Not Yet Recruiting | 50 | Norway |
| 30 | Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse Cancer & Oncology · Gustave Roussy, Cancer Campus, Grand Paris (NCT07871864) | Phase 3 | Recruiting | 530 | Denmark |
| 31 | Biomarkers Usefulness in the Screening of Hepatocellular Carcinoma in an European High-risk Cohort. Cancer & Oncology · Hospital Universitario La Paz (NCT07872319) | Other | Completed | 417 | Spain |
| 32 | Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer Cancer & Oncology · McGill University Health Centre/Research Institute of the McGill University Health Centre (NCT07871838) | Other | Recruiting | 50 | Canada |
| 33 | This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors Cancer & Oncology · LTZ Therapeutics, Inc. (NCT07878988) | Phase 1 | Recruiting | 152 | United States |
| 34 | A Study of QLS2401 Injection in Participants With Advanced Prostate Cancer Cancer & Oncology · Shanghai Qilu Pharmaceutical Research and Development Center LTD (NCT07869888) | Phase 1 | Not Yet Recruiting | 252 | N/A |
| 35 | Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer Cancer & Oncology · RemeGen Co., Ltd. (NCT07874282) | Phase 2 | Not Yet Recruiting | 200 | China |
| 36 | Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma Cancer & Oncology · University of Texas Southwestern Medical Center (NCT07878689) | Phase 2 | Not Yet Recruiting | 36 | United States |
| 37 | MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast Cancer Cancer & Oncology · Fudan University (NCT07875244) | Other | Active Not Recruiting | 1,024 | China |
| 38 | Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients Cancer & Oncology · Mundipharma (China) Pharmaceutical Co. Ltd (NCT07869797) | Other | Not Yet Recruiting | 378 | China |
| 39 | GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201) Cancer & Oncology · GI Innovation, Inc. (NCT07871435) | Phase 2 | Recruiting | 107 | United States |
| 40 | Prospective ctDNA Testing in Large B-Cell Lymphoma Cancer & Oncology · Peking University People's Hospital (NCT07878351) | Other | Recruiting | 100 | China |
| 41 | Follow-up After Oncological Resection by Endoscopic Colorectal ESD (Endoscopic Submucosal Dissection) Cancer & Oncology · University Hospital, Bordeaux (NCT07871227) | Other | Not Yet Recruiting | 1,200 | France |
| 42 | Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC Cancer & Oncology · NYU Langone Health (NCT07874490) | Phase 2 | Recruiting | 60 | United States |
| 43 | A Study of Treatment Delivery Preference In People With Kidney Cancer Cancer & Oncology · Memorial Sloan Kettering Cancer Center (NCT07872553) | Phase 4 | Recruiting | 40 | United States |
| 44 | SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer Cancer & Oncology · Shenyang Sunshine Pharmaceutical Co., LTD. (NCT07874984) | Phase 2 | Not Yet Recruiting | 220 | N/A |
| 45 | Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration Cancer & Oncology · M.D. Anderson Cancer Center (NCT07877220) | Other | Not Yet Recruiting | 200 | United States |
| 46 | Developing and Validating Health Education Module for Prostate Cancer Prevention Behavior in Iraqi Male University Staff Cancer & Oncology · Universiti Sains Malaysia (NCT07878663) | Other | Not Yet Recruiting | 160 | Iraq |
| 47 | Cross Immune Response Between Breast Carcinoma and Thyroid Autoimmunity: Impact on Prognosis and Treatment Cancer & Oncology · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (NCT07870148) | Other | Recruiting | 496 | Italy |
| 48 | PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Cancer & Oncology · German Cancer Research Center (NCT07877584) | Phase 3 | Not Yet Recruiting | 406 | N/A |
| 49 | Plasma DNA Methylation for Preoperative Classification of Renal Masses Cancer & Oncology · RenJi Hospital (NCT07874542) | Other | Recruiting | 240 | China |
| 50 | 68Ga- and 18F-CAIX PET Imaging Study Cancer & Oncology · Peking University First Hospital (NCT07875946) | Phase 1 | Not Yet Recruiting | 100 | China |
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Cancer & Oncology. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| pembrolizumab | Malignant Neoplasm Progression | 1,762 |
| nivolumab | Off Label Use | 819 |
| trastuzumab | Myelosuppression | 707 |
| rituximab | Off Label Use | 5,551 |
| paclitaxel | Myelosuppression | 1,062 |
Recalls & safety notices
FDA drug recall notices for medications related to Cancer & Oncology. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Cancer & Oncology, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
Sex Differences in Postoperative Outcomes for Men and Women With Colon Cancer in the US Military Health System.
View abstractOBJECTIVES: Biological, behavioral, and health care access differences between men and women may contribute to differences in colon cancer diagnosis and treatment. We compared postoperative outcomes between men and women with colon cancer in the universal access Military Health System (MHS) to better understand sex-based differences in surgery. METHODS: We identified patients with stage I to III colon adenocarcinoma receiving surgery in the Military Cancer Epidemiology (MilCanEpi) database between 2001 and 2014. Thirty-day postoperative outcomes included general cardiovascular and respiratory complications; infections (surgical site [SSI], urinary tract [UTI], and systemic); gastrointestinal (GI) complications (hemorrhage, bowel obstruction, ileus, intra-abdominal abscess, and anastomotic leakage); and hospital readmissions. Modified Poisson regression estimated adjusted rate ratios (ARRs) and 95% CIs in association with biological sex for the outcomes. RESULTS: The study included 1073 male (mean age=59.5±13.5 y) and 794 female (mean age=59.6±13.5 y) patients. In the 30-day postoperative period, general complication rates were not different by sex (ARR=1.03, 95% CI: 0.76-1.40 for women vs. men). Female sex was associated with higher rates of UTI (ARR=2.44, 95% CI: 1.63-3.65) and lower rates of GI complications (ARR=0.79, 95% CI: 0.69-0.90) relative to men. There were no sex differences in 30-day hospital readmissions (ARR=0.90, 95% CI: 0.76-1.08 for women vs. men). CONCLUSIONS: In the MHS, female sex was associated with higher rates of UTI and lower rates of GI complications relative to men undergoing colon cancer surgery. Factors other than health care access, such as biological differences in pelvic anatomy, physiology, or immune responses, may contribute to observed differences. |
American journal of clinical oncology | 2026 Oct 19 | PubMed |
| 02 |
Multifunctional Magneto‑Thermal Probe Enhances the Efficacy of Tumor Therapy as a Tumor Nanovaccine.
View abstractMagnetic hyperthermia therapy (MHT) is an emerging thermotherapeutic approach that has shown promising potential in cancer treatment. However, conventional MHT strategies exhibit limited capacity to activate anti-tumor immune responses, an essential factor for preventing cancer recurrence and metastasis. Therefore, improving the immunomodulatory efficacy of MHT remains a critical challenge. This study designed and developed a novel magneto-thermal probe, PSRNP, by conjugating anti-PD-L1 and RS09 peptides onto the surface of superparamagnetic iron oxide nanoparticles. The resulting PSRNP nanoprobes demonstrated excellent magneto-thermal conversion efficiency and favorable biocompatibility. In vivo analysis demonstrated that PSRNP-mediated MHT effectively remodels the tumor microenvironment. Meanwhile, PSRNP-mediated MHT showed superior immune activation effects, with a 5.14-fold increase in intratumoral CD86 cells and a 3.30-fold increase in CD137 cells compared with the FeO-mediated MHT group. Furthermore, PSRNP-mediated MHT potentiated the therapeutic efficacy of tumor-infiltrating lymphocyte therapy and prevented tumor recurrence after surgical resection. The PSRNP probe represents an innovative platform for improving the immunotherapeutic performance of MHT in solid tumors. The findings of this study establish a theoretical and experimental foundation for advancing MHT as a synergistic cancer treatment strategy. |
Small (Weinheim an der Bergstrasse, Germany) | 2026 Oct 18 | PubMed |
| 03 |
Patient-Facility Distance and Adjuvant Radiotherapy for WHO Grade 2-3 Meningioma.
View abstractOBJECTIVES: Adjuvant radiotherapy (RT) is commonly used after surgery for WHO grade 2 and 3 meningioma, but the role of patient-facility distance in RT receipt and dose/fractionation choice is not well defined. We examined whether travel distance was associated with receipt and type of adjuvant RT. METHODS: We used the National Cancer Database to identify adults diagnosed between 2010 and 2020 with surgically treated WHO grade 2 or 3 meningioma and a CROWFLY distance ≤250 miles. Patients were categorized into 3 groups according to WHO grade and extent of resection: grade 2 with gross total resection, grade 2 with subtotal resection/biopsy, and grade 3 with any resection. Outcomes were receipt of adjuvant RT, SRS/HF-SRS versus fractionated EBRT among classifiable RT recipients, and overall survival. RESULTS: Among 14,218 patients, 4063 (28.6%) received adjuvant RT. In multivariate models, the odds of RT receipt decreased with increasing distance, becoming statistically significant at 25 to <50 miles and remaining lower in more distant bins. Among 2767 classifiable RT recipients, greater distance was associated with higher odds of SRS/HF-SRS rather than fractionated EBRT. Distance was not associated with overall survival. Selected fine-bin estimates included OR=1.47 at 25 to <50 miles, OR=2.40 at 75 to <100 miles, and OR=3.08 at 150 to 250 miles. CONCLUSIONS: Greater patient-facility distance was associated with lower receipt of adjuvant RT and greater use of shorter stereotactic regimens among treated patients. These findings support geography as a predictor of both whether and how patients with higher-grade meningioma receive postoperative radiotherapy. |
American journal of clinical oncology | 2026 Oct 16 | PubMed |
| 04 |
Modern Radiotherapy for Axial Giant Cell Tumor of Bone: Impact of Gross Disease at Treatment Initiation.
View abstractOBJECTIVES: To evaluate outcomes of modern radiotherapy (RT) for giant cell tumor of bone (GCTB) in anatomically constrained axial sites and to assess the prognostic impact of disease burden at RT initiation. METHODS: We retrospectively reviewed consecutive patients with pathologically confirmed GCTB of the spine, sacrum, or skull treated with RT between 2006 and 2024 at a single institution. Patients treated with palliative intent and 1 patient lost to follow-up immediately after RT were excluded. Local recurrence-free survival (LRFS) and progression-free survival (PFS) were calculated from RT initiation. Gross disease at RT was defined as a radiographically visible lesion on CT and/or MRI at RT initiation. Survival was estimated using the Kaplan-Meier method and compared by the log-rank test; prognostic factors were explored using univariate analyses. RESULTS: Seventeen patients were included (postoperative RT, n=13; salvage RT, n=3; definitive RT, n=1) and treated with 3D-conformal RT (n=9), IMRT (n=3), or proton therapy (n=5). Median follow-up was 79.8 months. The 5-year LRFS and PFS rates were 75.1% and 68.3%, respectively. Four patients experienced local recurrence and 1 developed lung metastasis. Gross disease at RT initiation (n=8) was significantly associated with inferior LRFS (5 y LRFS: 46.9% vs. 100.0% without gross disease; P=0.018). CONCLUSIONS: In this cohort of axial GCTB treated with modern RT, gross disease at RT initiation was associated with inferior local control. Outcomes appeared more favorable when RT was delivered in the absence of gross disease, suggesting that maximal safe debulking before RT may be relevant in selected anatomically constrained cases. |
American journal of clinical oncology | 2026 Oct 16 | PubMed |
| 05 |
Dual Metabolic Inhibition Via Vanadium-NO Synergistic Nanoplatform Potentiates Cancer Immunotherapy.
View abstractImmunotherapy has emerged as a pivotal strategy in cancer treatment. However, tumor metabolic reprogramming not only promotes cancer cell survival but also fosters an immunosuppressive tumor microenvironment (TME), thereby hindering immune activation. To address these challenges, we developed a novel multifunctional hybrid nanoplatform, termed VTLM, via microfluidics-assisted self-assembly of bioactive vanadium species and an arginine-based nitric oxide (NO) donor. This nanoplatform synergistically modulates tumor metabolism to potentiate antitumor immunity. Specifically, we observed that vanadium species in VTLM reduce pyruvate kinase M2 (PKM2) expression and enzymatic activity, which may contribute to the suppression of tumor glycolysis, while tumor cell-targeted NO release induces mitochondrial damage, ultimately enforcing a dual metabolic blockade. This strategy overcomes the metabolic plasticity of tumor cells, a major obstacle in single-pathway metabolic targeting. Importantly, VTLM-induced metabolic collapse not only drives lactate depletion within the TME but also promotes immunogenic cell death, thereby reversing immunosuppression and amplifying antitumor responses. Furthermore, VTLM exhibited marked therapeutic efficacy in a 4T1 subcutaneous tumor model, achieving an 80.7% tumor weight-based inhibition rate alongside robust intratumoral immune activation. Collectively, this study establishes a nanoplatform centered on multi-metabolic regulation, which may hold potential for further preclinical evaluation as a strategy to enhance cancer immunotherapy. |
Small (Weinheim an der Bergstrasse, Germany) | 2026 Oct 18 | PubMed |
| 06 |
DNA Nanostructures for Overcoming Cancer Drug Resistance: Mechanisms, Therapeutic Strategies, and Translational Challenges.
View abstractCancer drug resistance, a major cause of chemotherapy failure, arises from multiple interconnected barriers, including reduced intracellular drug accumulation, enhanced drug efflux, adaptive survival signaling, increased DNA repair, and redox or metabolic remodeling. To address these limitations, recent advances in programmable DNA nanostructures have provided new opportunities for constructing multifunctional nanotherapeutic platforms. This review examines how the structural characteristics of DNA nanostructures influence drug delivery, molecular regulation, and resistance modulation, and analyzes how different DNA nanoplatforms, including tetrahedral framework nucleic acids, DNA origami, DNA nanoflowers, spherical nucleic acids, and hybrid DNA assemblies, contribute to therapeutic regulation. It then highlights their applications in overcoming major resistance-associated barriers, such as inefficient cellular uptake, drug efflux, apoptosis evasion, DNA repair activation, and biochemical adaptation. Finally, it discusses the challenges in DNA nanostructure-based cancer therapy and proposes future directions for improving stability, intracellular delivery, tumor accumulation, immune safety, and scalable manufacturing. These advances suggest that DNA nanostructures may serve as next-generation programmable nanomedicine platforms for multilevel intervention against cancer drug resistance. |
Small (Weinheim an der Bergstrasse, Germany) | 2026 Oct 18 | PubMed |
| 07 |
Development and Evaluation of an Evidence-Based Operative Reporting Framework for Pediatric Surgical Oncology: A Translational Program of Research.
View abstractAccurate documentation of critical intraoperative oncologic findings is essential for the subsequent management of children with solid tumors. This program of research aimed to establish an evidence-informed framework for operative documentation and evaluate whether synoptic reporting improves documentation completeness compared with traditional narrative reporting. A sequential, multiphase translational program of research was undertaken. First, evidence-based surgical guidelines for Wilms tumor and rhabdomyosarcoma were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to identify surgical factors relevant to local control and subsequent treatment. These recommendations informed an international multidisciplinary Delphi consensus process to establish essential universal and tumor-specific intraoperative reporting elements and develop a standardized synoptic operative reporting template. The template was subsequently implemented across five pediatric oncology centers in a prospective before-and-after study. The primary outcome was complete documentation of six predefined critical intraoperative oncologic elements. Exploratory end-user feedback assessed usability and acceptability. The guideline development process generated evidence-based recommendations addressing key aspects of pediatric solid tumor surgery, including lymph node sampling, vascular involvement, surgical margins, tumor spillage, and residual disease. The International Delphi consensus subsequently established 15 consensus statements defining essential operative documentation, including universal and tumor-specific elements. Following implementation of synoptic reporting, complete documentation of all six predefined critical intraoperative elements increased from 3 of 73 narrative reports (4.1%) to 71 of 92 synoptic reports (77.2%), an absolute increase of 73.1 percentage points (p < 0.000001). Exploratory end-user evaluation demonstrated high perceived usability, with a mean System Usability Scale score of 81.1. This translational program establishes an evidence-informed framework for operative documentation in pediatric surgical oncology by linking evidence-based guideline development, international consensus, and implementation of a standardized synoptic reporting tool. Synoptic reporting substantially improved the completeness of documentation of critical intraoperative oncologic findings compared with narrative reporting. |
World journal of surgery | 2026 Oct 18 | PubMed |
| 08 |
Hammersmith Infant Neurological Examination: Prediction of neurodevelopmental delay in children born between 29 and 36 weeks of gestation.
View abstractAIM: To evaluate the ability of the Hammersmith Infant Neurological Examination (HINE) at 3 months 2 weeks corrected age to identify developmental difficulties at 2 years corrected age in infants born preterm between 29 and 36 weeks of gestation. METHOD: In this prospective cohort study, the HINE was administered at 3 months 2 weeks corrected age. Development was assessed at 2 years corrected age using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) and MacArthur-Bates Communicative Development Inventories. Developmental delay was defined using Bayley-4 scores less than 1 SD below the mean; expressive language delay was defined as a score less than the 10th centile for the number of spoken words expected for age. The cohort was largely free of brain lesions typically associated with cerebral palsy (5% intraventricular hemorrhage, with no other major brain lesions reported). Associations were examined using linear regression, screening performance using receiver operating characteristic curves, and incremental predictive value by comparing adjusted R across models, including perinatal and socioenvironmental factors with and without the HINE. RESULTS: A total of 174 infants were included in the analyses. The HINE total score was not associated with motor, cognitive, or language outcomes. Discriminative performance was poor (area under the curve = 0.48-0.57); adding the HINE total score to models including perinatal and socioenvironmental factors did not improve predictive performance. INTERPRETATION: A single HINE at 3 months 2 weeks corrected age has limited utility for identifying mild-to-moderate developmental difficulties in this population and should not be used alone to determine developmental surveillance needs. Longitudinal surveillance incorporating complementary sources of developmental, clinical, and socioenvironmental information may be more effective. |
Developmental medicine and child neurology | 2026 Oct 18 | PubMed |
| 09 |
Age Does Not Independently Predict Biochemical Recurrence in Prostate Cancer Following Radical Prostatectomy: A Comparative Analysis of 4223 pT2N0R0 Patients.
View abstractBACKGROUND: Whether younger age independently predicts biochemical recurrence (BCR) after radical prostatectomy (RP) remains controversial because previous studies have included heterogeneous pathological stages and treatment populations. We aimed to determine whether age independently predicts BCR following RP in patients with organ-confined, node-negative, margin-negative (pT2N0R0) prostate cancer. METHODS: We performed a retrospective multicenter cohort study of 4223 patients with pT2N0R0 prostate cancer treated with RP. Patients were stratified into ≤ 55 years (n = 875; including 223 aged < 50 years) and > 55 years (n = 3348). BCR was defined as a confirmed prostate-specific antigen level ≥ 0.2 ng/mL. Kaplan-Meier analyses, multivariable Cox regression, restricted cubic spline modeling, subgroup analyses, and sensitivity analyses were performed. RESULTS: Younger patients had lower PSA levels, lower Grade Group, and lower crude BCR rates than older patients (3.8% vs. 5.9%; p = 0.018). However, younger age was not independently associated with BCR after adjustment for clinicopathological variables (hazard ratio 0.52, 95% confidence interval 0.26-1.04; p = 0.075). Higher PSA and Grade Group 3-5 independently predicted recurrence (all p < 0.05). Age analyzed continuously, alternative age thresholds, restricted cubic spline modeling, and subgroup analyses consistently demonstrated no significant association between age and BCR. Limitations include the retrospective design, relatively short follow-up, and use of BCR as a surrogate endpoint. CONCLUSIONS: Among men with pT2N0R0 prostate cancer treated with RP, age was not a statistically significant independent predictor of BCR, although a clinically meaningful effect cannot be excluded. Postoperative risk stratification should rely on established pathological factors rather than age alone. |
The Prostate | 2026 Oct 18 | PubMed |
| 10 |
From data to personas: a multi-source approach to tailored online health information recommendation for ovarian cancer patients and caregivers.
View abstractOBJECTIVE: Ovarian cancer (OvCa) patients and caregivers face complex, evolving information needs, yet digital health platforms often lack tailoring. This study developed and validated computational personas to support a tailored recommender system (Health E-Librarian with Personalized Recommendations [HELPeR]) and address the cold-start problem, in which limited information about new users reduces the system's ability to generate relevant recommendations. MATERIALS AND METHODS: We used a mixed-methods design integrating 4 data sources: (1) online OvCa forum posts (n = 457; 60 users), (2) semi-structured interviews with patients and caregivers (n = 20), (3) clinical case notes from a caregiver support program, and (4) expert input from gynecologic oncology nurses. Forum data were manually annotated and analyzed using k-modes clustering to identify user subgroups. Qualitative data were analyzed using thematic analysis, and findings were integrated to construct and refine personas. RESULTS: Five distinct user clusters were identified from forum data. Integration of multi-source data yielded 15 personas (9 patients, 6 caregivers) representing trajectories from diagnosis to end-of-life care. Patient personas captured needs related to symptom management, treatment decision-making, financial concerns, and psychosocial support, while caregiver personas emphasized communication, emotional burden, self-care, and care coordination. Personas reflected dynamic, context-dependent needs and were validated for clinical realism through expert review. DISCUSSION: Persona-based modeling provides an interpretable framework for tailored recommendation and approximates digital twin approaches, helping mitigate cold-start limitations. CONCLUSION: Multi-source persona development is a feasible strategy for enabling tailored digital health interventions and improving tailored information delivery in oncology care. |
Journal of the American Medical Informatics Association : JAMIA | 2026 Oct 18 | PubMed |
| 11 | Patients gain potential options for treatment of advanced NSCLC: Trials show that ivonescimab combined with chemotherapy improved overall survival, and sunvozertinib improved progression-free survival. | Cancer | 2026 Oct 15 | PubMed |
| 12 |
Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting PLK1 to Impair CEP55-ESCRT-Associated Vesicular Damage Clearance.
View abstractOxaliplatin (L-OHP) is a first-line chemotherapeutic agent for advanced colorectal cancer (CRC) and postoperative adjuvant therapy. However, acquired L-OHP resistance remains a clinical obstacle. Here, we identify Tubocapsenolide A (TA), a natural withanolide isolated from Tubocapsicum anomalum, as a promising antitumor agent that suppresses CRC growth and sensitizes L-OHP-resistant CRC to L-OHP. Using a PROTAC-based target deconvolution strategy, we identify PLK1 as a direct molecular target of TA. PLK1 is elevated in L-OHP-resistant CRC and is associated with reduced patient sensitivity to L-OHP. Mechanistically, elevated PLK1 promotes CEP55 Ser436 phosphorylation and facilitates ESCRT recruitment to nuclear and mitochondrial budding sites. This process facilitates the clearance of L-OHP-induced damaged components through nuclear budding and TOM20/PDH mitochondrial-derived vesicles, thereby contributing to organelle homeostasis and cell survival. By inhibiting PLK1, TA interferes with this vesicle-associated damage clearance process, leading to intracellular accumulation of damaged components. This damage accumulation is accompanied by nucleolar stress and mitochondrial dysfunction, ultimately contributing to cell death. Collectively, our findings identify a previously unappreciated role of the PLK1-CEP55-ESCRT axis in vesicle-associated damage clearance during L-OHP resistance and support this axis as a potential therapeutic target. TA represents a promising lead compound for overcoming L-OHP resistance in CRC. |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026 Oct 18 | PubMed |
| 13 |
Primetime for the Gasdermins Seesaw in Intestinal Homeostasis and Digestive Disorders.
View abstractThe five pore-forming gasdermins (GSDMs, namely GSDMA-E) are best known for executing pyroptosis, a lytic and highly inflammatory form of programmed cell death. Accumulating evidence over the past decade has unveiled diverse nonlytic functions of GSDMs in digestive homeostasis and disease. GSDMs preserve intestinal barrier integrity and mucosal immunity under physiological conditions, whereas their dysregulated activation fuels tissue injury across a spectrum of digestive diseases, including inflammatory bowel disease, acute intestinal injury, radiation enteritis, acute pancreatitis, and liver disorders. Notably, the functional outcome of GSDM activation is highly context-dependent: the same protein can be either protective or injurious. This duality extends to digestive oncology, where GSDM-mediated pyroptosis can stimulate or suppress antitumor immunity. GSDM-targeted drugs, including GSDMD agonists, GSDMD inhibitors, and GSDME inhibitors, have shown encouraging efficacy in preclinical models, although none have yet reached the clinic. Here, we review the dual roles of GSDMs across the digestive system, outline the mechanistic basis of their form-, cell-, and tissue-specific functions, and discuss the progress and remaining challenges in GSDM-targeted therapy. |
Medicinal research reviews | 2026 Oct 18 | PubMed |
| 14 |
Does Barrett's Esophagus Length Still Matter? Contemporary Implications for Risk Stratification, Surveillance, and Endoscopic Therapy.
View abstractLonger Barrett esophagus (BE) segments are associated with worse outcomes than shorter segments. However, it remains uncertain whether BE length is still a clinically actionable variable in modern surveillance, risk stratification, and treatment pathways. We reviewed current literature on the relevance of BE length as a predictor of gastroesophageal reflux disease (GERD) severity, cancer risk, treatment outcomes, regression after treatment, and remission after ablation. BE length correlates with hiatal hernia size, esophageal dysmotility, esophagitis, and acid exposure time. Long-segment BE carries a greater risk of dysplasia or progression to esophageal adenocarcinoma than short-segment BE, although smaller segments are not risk-free. Longer BE length was associated with treatment failure and increased post-treatment pain. BE length also predicted recurrence of BE, dysplasia, or adenocarcinoma after endoscopic ablation therapy. In conclusion, most current studies report BE outcomes without stratifying results by length. BE length, however, functions as a continuous clinical variable that influences multiple aspects of care, including progression risk, surveillance intervals, treatment complexity, likelihood of eradication, recurrence after therapy, and incorporation into emerging prediction models. In other words, the contemporary importance of length lies less in preserving a historical cutoff than in recognizing length as one component of multidimensional risk stratification. |
The American surgeon | 2026 Oct 18 | PubMed |
| 15 |
Harnessing Methylselenol (CH(3)SeH): A Highly Effective Platform for Stimuli-Responsive Delivery With Therapeutic Potential.
View abstractMethylselenol (CHSeH) is not only a key selenium (Se) metabolite but also a potent therapeutic molecule. Chemical tools for stimulus-responsive delivery of CHSeH should be crucial for exploring Se-related biomedicine. Nevertheless, the classical 1,6-self-immolation is inefficient in releasing the poorly leaving selenol, and donation platforms for triggerable release of the CHSeH remain lacking. Herein, we report the first general responsive platform (Triggered Donation for MethylSelenol, termed TD-MSe) via fast intramolecular amino-activated methylselenocarbamates (t = 5 s at pH 7.4), enabling the efficient cyclization release of CHSeH without electrophilic byproducts. We leverage the caged TD-MSe motifs to successfully create triggered donors that are stable before activation but can liberate CHSeH under different stimulus conditions in vitro and in live cells. Additionally, we demonstrate that the tumor-associated oxidoreductase (hNQO1)-triggered CHSeH donor was activated in hNQO1-positive HT-29 cells but not in hNQO1-negative cells. Moreover, we can use the CHSeH prodrug to selectively kill metastatic cells of hNQO1-overexpressing cancer types, providing a promising therapeutic strategy for difficult-to-treat diseases. We anticipate that the new-release chemistry will be widely applied for developing advanced tools toward smart selenol delivery and therapy. |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026 Oct 18 | PubMed |
| 16 |
Therapeutic Peptide-Programmed Liquid-Crystalline Topology Switching for pH-Gated Postoperative Cancer Immunotherapy.
View abstractStimuli-responsive depots for postoperative cancer therapy often treat therapeutic payloads as passive cargo, resulting in premature leakage and limited on-demand activation. Herein, we report a therapeutic peptide-programmed liquid-crystalline depot in which the Vpr-derived antitumor peptide (VDAP) functions simultaneously as an immunotherapeutic effector and a supramolecular topology regulator. At physiological pH, cationic α-helical VDAP was electrostatically anchored by oleic acid-containing lipid domains, reinforcing a compact inverse hexagonal (H) topology associated with reduced peptide diffusion. In the acidic postoperative tumor microenvironment, protonation of oleic acid could disrupt anionic anchoring, whereas histidine protonation within VDAP amplified intrachannel electrostatic repulsion. This cooperative peptide-lipid charge reprogramming could drive graded liquid-crystalline topology remodeling from a diffusion-restrictive H organization to a more interconnected bicontinuous cubic Im3̄m network, consistent with increased pH-responsive peptide release. In an orthotopic incomplete-resection breast tumor model, the depot induced immunogenic tumor destruction, enhanced damage-associated molecular pattern release, promoted dendritic cell maturation and CD8 T cell infiltration, and reshaped the immunosuppressive surgical bed. These results demonstrate that electrostatic-topology-gated VDAP-enabled supramolecular topology switching provides effective adaptive local cancer immunotherapy, effectively suppressing postoperative tumor recurrence and attenuating pulmonary metastasis. |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026 Oct 18 | PubMed |
| 17 |
HECTD1 Directs HIF-1α to Facilitate Intestinal Inflammation and Carcinogenesis via Promoting Th17 Differentiation and Glycolysis.
View abstractTargeting glucose metabolism in Th17 cells may be beneficial for treating inflammatory bowel disease (IBD) and colitis-associated cancer (CAC), however, the molecular mechanisms orchestrating Th17 cell metabolism remain unclear. Here, we revealed that HECTD1 regulates IGF2BP3-dependent HIF-1α translation to promote Th17 cell glycolysis and differentiation and that HECTD1 expression correlates with IBD and CAC pathogenesis. T-cell-specific deletion of HECTD1 mitigated the severity of colitis and CAC in murine models. RNA-seq revealed enrichment of Th17 differentiation, glycolysis/gluconeogenesis, and HIF-1 signaling pathways among differentially expressed genes between HECTD1-sufficient and HECTD1-deficient CD4 T cells. Consistently, loss of HECTD1 suppressed Th17 cell differentiation both in vitro and in vivo, and suppressed glycolytic metabolism and HIF-1α activity, revealing the mechanism underlying its protective effects against IBD and CAC. Mechanistically, HECTD1 potentiates mA-based HIF-1α translation by mediating IGF2BP3 K63-linked ubiquitination to promote the binding of IGF2BP3 with the translation initiation machinery of Hif1a mRNA. Reciprocally, HIF-1α acts as a key transcription factor that promotes Hectd1 gene expression, establishing a distinct positive feedback loop. Our findings highlight a self-reinforcing feedback mechanism in which HECTD1 and HIF-1α engage in mutual regulation to dictate Th17 cell fate and metabolic reprogramming, providing novel potential IBD and CAC treatments targeting HECTD1. |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026 Oct 18 | PubMed |
| 18 |
Harnessing the ion transportome to treat cancer.
View abstractDespite significant advances in early detection and therapeutic opportunities, cancer remains a critical global health challenge. The greatest barrier to reducing cancer-associated mortality is the persistent problem of therapeutic resistance and metastasis. Standard treatment approaches, including surgery combined with chemotherapy and radiation, are effective for many patients with localised disease. However, a substantial proportion of patients will experience recurrence and therapy resistance, leading to treatment failure and poor outcomes. This adverse prognosis for patients highlights the critical need to identify new therapeutic targets capable of improving long-term survival. The ion transportome comprises ion channels, solute transporters and pumps that regulate controlled movement of sodium (Na), potassium (K), calcium (Ca), chloride (Cl) and hydrogen (H) across cell membranes. Ion transport is central to many cellular processes, including cell growth, volume regulation, proliferation and migration. In many solid tumours, the finely tuned ionic balance becomes dysregulated, with aberrant expression or activity of membrane transport proteins being closely linked to many of the hallmarks of cancer. Ion channel modulation using pharmacological agents designed to treat channelopathies has demonstrated promise in suppressing cancer progression in preclinical models. Thus, targeting ion-driven vulnerabilities within solid tumours may complement existing therapies to overcome resistance and improve patient outcomes. The dynamic nature of ion transport mechanisms means that addressing critical research questions regarding their suitability as pharmacological targets is challenging, highlighting the need to develop innovative approaches to study these processes in oncology. |
The Journal of physiology | 2026 Oct 18 | PubMed |
| 19 |
Thioredoxin-2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation.
View abstractOsteoporosis is a prevalent age- and disease-associated skeletal disorder characterized by bone loss, remodeling imbalance, and vascular niche deterioration, yet how endothelial redox dysfunction drives this process remains unclear. Here, we identify mitochondrial thioredoxin-2 (TRX2) as an endothelial safeguard against osteoporotic bone loss. TRX2 was markedly reduced in aging bone vascular endothelial cells, and endothelial Trx2 deficiency accelerated skeletal degeneration by suppressing osteogenic activity and enhancing osteoclastogenesis. Mechanistically, TRX2 directly bound FOXO3a through a redox-sensitive Cys90-Cys31 disulfide interaction, retaining FOXO3a at the mitochondrial outer membrane and limiting its nuclear translocation. TRX2 loss or oxidative stress disrupted this complex, enabling FOXO3a-dependent transcriptional activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and generating a pro-osteoclastogenic vascular niche. TRAIL neutralization or endothelial TRX2 restoration attenuated ovariectomy-induced osteoporosis by preserving angiogenic-osteogenic coupling. These findings establish the endothelial TRX2-FOXO3a-TRAIL axis as a vascular redox checkpoint and potential therapeutic target for osteoporosis. |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026 Oct 18 | PubMed |
| 20 |
Oral Astilbin Nanogels Modulate Senescence-Associated CD4(+) T Cells and Promote T(reg) Induction in Aged Mice with Colitis.
View abstractInflammatory bowel disease (IBD) in older individuals is characterized by immune senescence and deteriorating intestinal homeostasis, both of which limit the efficacy of current therapies. Here, we develop fluorinated β-glucan/pectin nanogels (F-Ast@NGs) for oral delivery of astilbin, a natural flavonoid with anti-inflammatory and immunoregulatory activities. This multifunctional platform integrates gastrointestinal protection, colon-targeted release, and local immune modulation. The β-glucan shell preserves nanogel stability during upper gastrointestinal transit while enabling β-glucanase-responsive disassembly in the colon. Fluorocarbon segments enhance mucus penetration, and the pectin matrix prolongs colonic retention, promoting drug accumulation at inflamed sites. In aged mice with dextran sulfate sodium (DSS)-induced colitis, F-Ast@NGs alleviate disease severity, attenuate senescence-associated features of colonic CD4 T cells, and enhance Foxp3 regulatory T cell (T) responses. Concurrently, the β-glucan/pectin nanogel matrix contributes to increased short-chain fatty acid production and favorable alterations in gut microbial composition. Notably, the therapeutic efficacy of F-Ast@NGs is markedly attenuated in Foxp3 T-depleted mice, supporting an important role for T-mediated immunoregulation. Collectively, F-Ast@NGs enable precise colonic delivery while coordinately remodeling the intestinal immune and microbial microenvironment, providing a promising oral nanotherapeutic strategy for colitis in aged hosts. |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2026 Oct 18 | PubMed |
| 21 |
Alkalizer-based gastroretentive floating tablets of amoxicillin for localized gastric delivery.
View abstractINTRODUCTION: infection is a leading cause of peptic ulcer disease, yet amoxicillin trihydrate (AMX) efficacy is limited by its acid-catalyzed degradation and rapid gastric emptying. This study aimed to develop alkalizer-based gastroretentive floating tablets to enhance localized gastric-delivery and improve AMX stability under gastric conditions. MATERIALS AND METHODS: Floating tablets were prepared by direct compression using HPMC K100M, sodium-bicarbonate and microcrystalline-cellulose. A 2 factorial-design (RStudio-v4.3.3) was used to optimize microenvironmental pH, floating lag time (FLT) and drug release. Optimized tablets were characterized for micromeritic properties, XRD, SEM, buoyancy, swelling, drug release, anti- activity and gastric retention in Sprague-Dawley rats. RESULTS: The optimized formulation achieved a microenvironmental pH of 7.20 ± 0.26, FLT of 15.84 ± 0.50 s, and total floating time of approximately 12 h. Cumulative AMX release reached 98.49 ± 1.69% over 12 h with non-Fickian kinetics, and XRD/SEM analysis indicated reduced crystallinity and increased amorphous character of AMX within the hydrated matrix. The formulation showed significant anti- activity and prolonged gastric retention. CONCLUSION: Alkalizer-based gastroretentive floating AMX tablets combined microenvironmental pH modulation with sustained gastric-retention, supporting their potential as a localized strategy for improved eradication. |
Therapeutic delivery | 2026 Oct 18 | PubMed |
| 22 |
Peripheral precocious puberty in a 4-month-old infant associated with an ESR1 variant: a case report.
View abstractPrecocious puberty (PP) refers to pubertal onset before 8 years in females and 9 years in males. We present a rare case of a 6-year and 7-month-old Jordanian girl with peripheral PP onset at 4 months of age. Clinical evaluation revealed vaginal spotting, premature thelarche, advanced bone age, and recurrent uterine bleeding requiring multiple transfusions. Imaging demonstrated a progressive cervicovaginal mass and endometrial polyps. Histopathology identified atypical hyperplasia/endometrioid intraepithelial neoplasia. Gonadotropins remained persistently suppressed, excluding central PP. Whole-exome sequencing (WES) identified a heterozygous likely-pathogenic ESR1 missense variant (NM_000125.3; c.1610A > C; p.Tyr537Ser), previously linked to estrogen-independent receptor activation in breast cancer. Tamoxifen produced partial clinical response with subsequent recurrence; the patient is now on combined letrozole-tamoxifen therapy. This case highlights the value of WES in unexplained PP and suggests that gain-of-function ESR1 variants may drive peripheral PP through receptor hypersensitivity. |
Oxford medical case reports | 2026 Oct | PubMed |
| 23 |
Targeting Cancer-Associated Fibroblasts with Small-Molecule Inhibitors: Molecular Mechanisms and Therapeutic Potential.
View abstractThe multifaceted role of cancer-associated fibroblasts (CAFs) in orchestrating extracellular matrix remodeling, immune evasion, and therapeutic resistance positions these stromal cells as critical yet underexploited nodes in the tumor microenvironment (TME). While small-molecule agents offer practical advantages over biologics for stromal modulation, a systematic understanding of their mechanistic diversity and translational barriers remains incomplete. To address this gap, this review consolidates current knowledge on the principal signaling axes-TGF-β/STAT3, NF-κB, Notch, Hedgehog, PI3K/AKT, and CXCL12/CXCR4-that sustain CAF activation and pathogenic functions. Distinct from prior CAF reviews, particular emphasis is placed on the structure-activity refinement (SAR) of fibroblast activation protein (FAP)-targeted small-molecule ligands and on pharmacokinetic optimization via fatty acid conjugation and porphyrin integration that substantially improve tumor retention. Representative pharmacological inhibitors-including nicotinamide N-methyltransferase (NNMT), phosphodiesterase 5A (PDE5A), and NADPH oxidase 4 (NOX4) inhibitors-are evaluated for their capacities to remodel immunosuppressive networks, with attention to their synergism when combined with chemotherapeutic agents, immune checkpoint blockers, or antibody-drug conjugates. Emerging evidence indicates that CAF heterogeneity and plasticity pose fundamental obstacles to monotherapy efficacy, whereas rationally designed combination regimens produce superior antitumor outcomes in preclinical models. We further identify key knowledge gaps-including the lack of CAF-subset-selective drugs, unresolved pharmacotoxicology of pan-FAP inhibition, and limited biomarker-guided patient stratification-and discuss translational and regulatory barriers that must be overcome before widespread clinical adoption. Collectively, this review argues that the future of CAF-directed pharmacotherapy lies not in indiscriminate depletion but in subset-selective reprogramming, and that clinical success will increasingly depend on biomarker-guided patient stratification and mechanistically anchored multidrug scheduling rather than on isolated target inhibition. |
Drug design, development and therapy | 2026 | PubMed |
| 24 |
Synchronous laryngeal squamous cell carcinoma and papillary urothelial carcinoma of the bladder: a case report and literature review.
View abstractSynchronous primary malignancies are defined as two histologically distinct tumors arising in different anatomical sites within six months. Although tobacco exposure is a recognized shared carcinogenic factor, the coexistence of laryngeal squamous cell carcinoma and bladder urothelial carcinoma remains rare. We report the case of a 75-year-old man with a 40 pack-year smoking history who presented with progressive dysphonia. Imaging revealed a locally advanced laryngeal tumor and an incidental bladder lesion. Histopathological examination confirmed a well-differentiated laryngeal squamous cell carcinoma and a low-grade non-muscle-invasive papillary urothelial carcinoma of the bladder, fulfilling the Warren and Gates criteria for synchronous primary tumors. The patient underwent induction chemotherapy for laryngeal preservation and transurethral resection of the bladder tumor followed by surveillance. This case highlights the importance of systematic screening and multidisciplinary management in high-risk patients. |
Oxford medical case reports | 2026 Oct | PubMed |
| 25 |
Phyllodes Tumors of the Breast in 2026: A Contemporary Narrative Review of Diagnosis, Surgical Margins, Prognosis, and Emerging Therapies.
View abstractPhyllodes tumors of the breast are rare fibroepithelial neoplasms characterized by significant heterogeneity regarding morphology, biological behavior, and clinical outcome. This review summarizes current developments in the diagnosis, histopathological and molecular classification, therapeutic management, and emerging technologies associated with phyllodes tumors of the breast. A literature search was conducted across PubMed/MEDLINE, Scopus, Embase, and Google Scholar, focusing on publications from the 2000-2026 period. The literature search covered publications from January 1, 2000, to September 30, 2026, and was last updated on September 30, 2026. Mammography, ultrasound, and magnetic resonance imaging contribute to preoperative assessment, although significant diagnostic overlap with fibroadenomas persists. Core needle biopsy is a key diagnostic tool, yet lesion heterogeneity can limit the accuracy of histological classification. Advances in molecular pathology have identified mutations and pathways associated with the progression and aggressiveness of phyllodes tumors, though these have not yet replaced morphological assessment. Surgical excision with negative margins remains the primary therapeutic approach, while the risk of local recurrence depends on histological grade, surgical margins, and other clinicopathological characteristics. Radiotherapy in phyllodes tumors of the breast appears to offer benefits primarily regarding local control in selected high-risk cases. Emerging technologies, including artificial intelligence, radiomics, and digital pathology, are proving to be promising tools for diagnosis, grading, and prognostic assessment. Overall, modern management of phyllodes tumors of the breast is shifting toward more personalized and multifactorial approaches. |
Cureus | 2026 Oct | PubMed |

